03.03.2017
MorphoSys AG DE0006632003
DGAP-News: MorphoSys Announces That Its Licensee Janssen Has Reported New Data From Two Phase 3 Studies of Guselkumab in Plaque Psoriasis
DGAP-News: MorphoSys AG / Key word(s): Study
MorphoSys Announces That Its Licensee Janssen Has Reported New Data From Two
Phase 3 Studies of Guselkumab in Plaque Psoriasis (news with additional
features)
03.03.2017 / 14:31
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, March 3, 2017
MorphoSys Announces That Its Licensee Janssen Has Reported New Data From
Two Phase 3 Studies of Guselkumab in Plaque Psoriasis
- Janssen presents results from phase 3 studies VOYAGE 2 and NAVIGATE in
patients with moderate-to-severe plaque psoriasis at the American
Academy of Dermatology (AAD) 2017 annual meeting.
- Both studies met all primary endpoints, according to the abstracts
submitted by Janssen to the AAD 2017 meeting.
- According to a press release issued by Janssen today, data from
Janssen's VOYAGE 2 study "showed that patients treated with guselkumab
experienced significant improvements in skin clearance and other
measures of disease activity compared with placebo, and significantly
greater improvements compared with the anti-tumor necrosis factor
(TNF)-alpha treatment Humira(R) (adalimumab)."
- Furthermore, according to Janssen's press release, data from Janssen's
NAVIGATE study "showed that patients who had an inadequate response
following treatment with the anti-interleukin (IL)-12/23 monoclonal
antibody STELARA(R) (ustekinumab) and who then switched to guselkumab,
showed significantly greater improvements in skin clearance compared
with patients who continued to receive ustekinumab".
- Guselkumab, a fully human anti-IL-23 monoclonal antibody developed by
Janssen, was generated utilizing the HuCAL antibody library technology
licensed from MorphoSys.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
announced today that its licensee Janssen Research & Development, LLC
(Janssen), has reported today results from two clinical phase 3 studies of
guselkumab in patients with moderate-to-severe plaque psoriasis. Janssen
will present the data from its VOYAGE 2 and NAVIGATE studies at the
American Academy of Dermatology (AAD) annual meeting, held from March 3-7,
2017 in Orlando, Florida/USA. Guselkumab, a fully human anti-IL-23
monoclonal antibody developed by Janssen, was generated utilizing the HuCAL
antibody library technology licensed from MorphoSys.
"Following on from the successful phase 3 VOYAGE 1 study in moderate to
severe plaque psoriasis reported in October 2016, we are excited about the
positive results from two more phase 3 studies with guselkumab reported by
Janssen today", said Dr. Marlies Sproll, Chief Scientific Officer of
MorphoSys AG. "Plaque psoriasis is a chronic disease affecting millions of
patients worldwide. We hope this therapy will be made available for
patients living with moderate to severe plaque psoriasis and can make a
contribution to treating their conditions. As previously reported by
Janssen, the results of these studies were already included in Janssen's
regulatory filings of guselkumab in the US and Europe".
Further detailed information about the clinical study results can be found
in a press release issued by Janssen today.
About Psoriasis
Psoriasis is a chronic, autoimmune inflammatory disorder that results in
the overproduction of skin cells, characterised by raised, inflamed, scaly,
red lesions, or plaques, which can cause itching and physical pain. It is
estimated that as many as 125 million people worldwide have psoriasis,
including 14 million Europeans, and approximately 20% of people affected
have cases that are considered moderate to severe.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic pipeline of more than 100 human antibody drug candidates for
the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to
name just a few. With its ongoing commitment to new antibody technology and
drug development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit http://
www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R),
Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the
MorphoSys Group.
Humira(R) is a registered trademark of AbbVie Inc.
Stelara(R) is a registered trademark of Janssen Biotech, Inc.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-
looking statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=TIVSLOTRCW
Document title: Media Release
---------------------------------------------------------------------------
03.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
550243 03.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR